AZEB LEMMA: Open Payments
NPI 1235591975 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,735 in 95 payments from 32 companies in 2025. Trend: 2023 $1,319 · 2024 $1,530 · 2025 $1,735
Food & beverage: $1,447Education: $288
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $250 |
| Novartis Pharmaceuticals Corporation | 23 | $234 |
| PFIZER INC. | 13 | $196 |
| Janssen Biotech, Inc. | 7 | $182 |
| ABBVIE INC. | 8 | $138 |
| Eisai Inc. | 5 | $115 |
| Genentech USA, Inc. | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Pharmacosmos Therapeutics Inc. | 2 | $36 |
| BeOne Medicines USA, Inc. | 2 | $35 |
Products named: DARZALEX, Lenvima, LUTATHERA, KISQALI, EPKINLY, PADCEV, IBRANCE, BRUKINSA.
Industry payments across IN — which companies pay providers there.
